These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K; J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631 [TBL] [Abstract][Full Text] [Related]
7. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families. Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635 [TBL] [Abstract][Full Text] [Related]
8. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700 [TBL] [Abstract][Full Text] [Related]
10. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291 [TBL] [Abstract][Full Text] [Related]
11. Acquired Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239 [TBL] [Abstract][Full Text] [Related]
12. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not? Vos S; van Diest PJ; Moelans CB Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109 [TBL] [Abstract][Full Text] [Related]
13. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium. Dimitrova D; Ruscito I; Olek S; Richter R; Hellwag A; Türbachova I; Woopen H; Baron U; Braicu EI; Sehouli J Tumour Biol; 2016 Sep; 37(9):12329-12337. PubMed ID: 27297669 [TBL] [Abstract][Full Text] [Related]
14. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259 [TBL] [Abstract][Full Text] [Related]
15. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112 [TBL] [Abstract][Full Text] [Related]
16. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer. Li N; McInerny S; Zethoven M; Cheasley D; Lim BWX; Rowley SM; Devereux L; Grewal N; Ahmadloo S; Byrne D; Lee JEA; Li J; Fox SB; John T; Antill Y; Gorringe KL; James PA; Campbell IG J Natl Cancer Inst; 2019 Dec; 111(12):1332-1338. PubMed ID: 30949688 [TBL] [Abstract][Full Text] [Related]
17. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hansmann T; Pliushch G; Leubner M; Kroll P; Endt D; Gehrig A; Preisler-Adams S; Wieacker P; Haaf T Hum Mol Genet; 2012 Nov; 21(21):4669-79. PubMed ID: 22843497 [TBL] [Abstract][Full Text] [Related]
18. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299 [TBL] [Abstract][Full Text] [Related]
19. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508 [TBL] [Abstract][Full Text] [Related]
20. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]